Joon Ho Kwon

Dr. Joon Ho Kwon

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in European Radiology
Verified
Journal Article
Closed access
PDF file
JKJoon Ho Kwon
Joon Ho Kwon
MKMan-Deuk Kim
Man-Deuk Kim
KHKichang Han
Kichang Han
WCWoosun Choi
Woosun Choi
YKYong Seek Kim
Yong Seek Kim
DLDo Yun Lee
Do Yun Lee

1 December 2018 in Radiology
Verified
Journal Article
Closed access
KHKichang Han
Kichang Han
SSSeok Kyo Seo
Seok Kyo Seo
MKMan-Deuk Kim
Man-Deuk Kim
GKGyoung Min Kim
Gyoung Min Kim
JKJoon Ho Kwon
Joon Ho Kwon
DLDo Yun Lee
Do Yun Lee
Purpose To evaluate the effectiveness of catheter-directed sclerotherapy (CDS) with 95% ethanol in patients with primary or recurrent ovarian endometriomas. Materials and Methods In this prospective study, 14 participants (mean age, 32 years; range, 20-44 years) who underwent CDS for ovarian endometrioma from March 2015 to December 2017 were evaluated. Diagnosis was based on symptoms and imaging studies. To assess the impact of CDS on ovarian reserve, serum anti-Müllerian hormone (AMH) was measured before CDS and 6 months after CDS. Serum cancer antigen 125 (CA-125) levels were also measured at the same time points. Follow-up US was performed 1, 3, and 6 months after CDS and biannually thereafter to monitor potential cyst size change and recurrence. Comparison of AMH, CA-125, and cyst size before and after CDS was performed by using the paired t test or Wilcoxon signed-rank test. Results Mean endometrioma size decreased from 5.8 cm ± 2.2 to 1.1 cm ± 1 (P ˂ .001). During a mean follow-up of 12.7 months (range, 6.1-23.0 months), there were no recurrences of endometrioma. Pain was relieved in all participants, with a decrease in serum CA-125 level (P = .001). There was no difference in serum AMH level before and 6 months after CDS, indicating well-preserved ovarian function (4.29 ng/mL ± 2.47 vs 4.36 ng/mL ± 1.94, respectively; P > .875). There were no procedure-related complications. Conclusion Catheter-based sclerotherapy with 95% ethanol can lead to better short-term clinical outcomes and well-preserved ovarian function for patients with endometriomas. © RSNA, 2018.

1 October 2019 in Journal of Vascular Surgery
Verified
Journal Article
Open access
HJHyun Chel Joo
Hyun Chel Joo
YYYoung-Nam Youn
Young-Nam Youn
JKJoon Ho Kwon
Joon Ho Kwon
JWJong Yun Won
Jong Yun Won
DLDo Yun Lee
Do Yun Lee
KYKyung-Jong Yoo
Kyung-Jong Yoo
Although hybrid arch repair has gained widespread application as an alternative option for high-risk patients, concerns about its long-term durability remain an important issue. The aim of this study was to investigate late complications after hybrid arch repair. From January 2002 to December 2017, hybrid arch repair was performed in 65 patients with aortic arch disease (median age, 66.1 years; range, 41-86 years). Hybrid arch repair was defined as debranching involving at least one supra-aortic vessel bypass and simultaneous or staged endovascular thoracic stent grafting. We retrospectively analyzed late complications including reintervention, open conversion, and aortic-related death. The median follow-up period was 60.1 months (range, 1-170 months). The in-hospital mortality rate was 6% (4/65). Except for early death (n = 4) and early open conversion (n = 2), late complications were observed in 25 patients (25/59 [42%]). The median time interval between the initial procedure and late complication was 36.6 months (range, 1-92 months). Late complications included delayed type I endoleak (n = 8), distal stent-induced new entry (n = 3), stent migration (n = 3), retrograde type A dissection (n = 2), aortopulmonary fistula (n = 2), aortoesophageal fistula (n = 1), stent fracture (n = 1), infection (n = 1), and sudden death (n = 4). Six of these patients (10%) underwent late open conversion. The overall survival rates at 3 years and 6 years were 71.1 ± 7.4% and 57.2 ± 11.3%, respectively. The aortic event-free rates at 3 years and 6 years were 52.1 ± 7.3% and 39.4 ± 10.3%, respectively. Late complications in hybrid arch repair occurred in a substantial proportion of patients during midterm follow-up. Regardless of zone type, the incidence of late complications was relatively high. This study suggests that timely reintervention and open conversion are important for rescuing patients, but repeated reinterventions and conservative strategies are not recommended. Aggressive management and life-long surveillance after hybrid arch repair are mandatory for better outcomes.

1 January 2013 in European Journal of Radiology
Verified
Journal Article
Closed access
JKJoon Ho Kwon
Joon Ho Kwon
EKEun-Kyung Kim
Eun-Kyung Kim
HLHye Sun Lee
Hye Sun Lee
HMHee Jung Moon
Hee Jung Moon
JKJin Young Kwak
Jin Young Kwak

1 January 2018 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
HJHae Do Jung
Hae Do Jung
JKJongchan Kim
Jongchan Kim
HAHyun Kyu Ahn
Hyun Kyu Ahn
JKJoon Ho Kwon
Joon Ho Kwon
KHKichang Han
Kichang Han
Joo Yong LeeJoo Yong Lee
Joo Yong Lee
Jung HD, et al. Investig Clin Urol. 2018 Sep;59(5):348-354. https://doi.org/10.4111/icu.2018.59.5.348

1 August 2012 in American Journal of Roentgenology
Verified
Journal Article
Closed access
WCWoo-Suk Chung
Woo-Suk Chung
KLKwang-Hun Lee
Kwang-Hun Lee
MPMi-Suk Park
Mi-Suk Park
YLYeo Jin Lee
Yeo Jin Lee
JKJoon Ho Kwon
Joon Ho Kwon
MKMyeong-Jin Kim
Myeong-Jin Kim
OBJECTIVE. The purpose of this article is to assess CT enhancement patterns of hepatocellular carcinoma (HCC) within 1 month after transarterial chemoembolization (TACE) using drug-eluting beads and to determine whether enhancement patterns may be useful for predicting local tumor progression. MATERIALS AND METHODS. Forty-one patients with 50 HCCs underwent CT within 1 month after TACE with drug-eluting beads. Two blinded readers independently reviewed the arterial phase images and classified enhancement patterns as follows: no enhancement, peripheral ring enhancement, and peripheral nodulelike enhancement. Enhancement patterns were correlated with time to tumor progression of enhancing tissue by log-rank test. RESULTS. In the group with no enhancement, 92.3% (24/26) had not progressed and 7.7% (2/26) showed progression; for peripheral ring enhancement, 83.3% (10/12) had not progressed and 16.7% (2/12) showed progression; and for peripheral nodulelike enhancement, 16.7% (2/12) had not progressed and 83.3% (10/12) showed progression. The time to progression of enhancing tissue was significantly different between the group with no enhancement plus peripheral ring enhancement and the group with peripheral nodulelike enhancement (p < 0.001). CONCLUSION. Analysis of enhancement patterns at the arterial phase of the first follow-up CT after TACE with drug-eluting beads is helpful for predicting progression of treated HCC.